Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Lucitanib |
Trade Name | |
Synonyms | E-3810|AL3810 |
Drug Descriptions |
Lucitanib (E-3810) is a multi-tyrosine kinase receptor inhibitor of VEGFR 1-3, DDR2, PDGFRA, and FGFR1-2, that may inhibit tumor angiogenesis, prevent tumor cell proliferation, and induce tumor cell death (PMID: 27988457, PMID: 24696502, PMID: 31619444). |
DrugClasses | DDR1 Inhibitor 8 DDR2 inhibitor 7 FGFR1 Inhibitor 26 FGFR2 Inhibitor 20 PDGFR-alpha Inhibitor 10 VEGFR Inhibitor (Pan) 33 |
CAS Registry Number | 1058137-23-7 |
NCIT ID | C95726 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Abemaciclib + Fulvestrant + Lucitanib | Abemaciclib Fulvestrant Lucitanib | 0 | 0 |
Alpelisib + Lucitanib | Alpelisib Lucitanib | 1 | 0 |
Fulvestrant + Lucitanib | Fulvestrant Lucitanib | 0 | 0 |
Fulvestrant + Lucitanib + Palbociclib | Fulvestrant Lucitanib Palbociclib | 0 | 0 |
Lucitanib | Lucitanib | 6 | 5 |
Lucitanib + Nivolumab | Lucitanib Nivolumab | 0 | 2 |
Lucitanib + Rucaparib | Lucitanib Rucaparib | 0 | 1 |